Intervention

bortezomib

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 21 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials21

Recruiting0

Common conditions25

Lead sponsors shown11

Clinical trials

21 shown

Bortezomib for the Treatment of Refractory Rheumatoid ArthritisNCT05805891 · 2023-12-01

Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung CancerNCT00798720 · 2008-12-01

Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid TumorsNCT00620295 · 2007-03-01

Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid TumorsNCT00667641 · 2007-03-01

Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant MesotheliomaNCT00458913 · 2007-02-01

Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung CancerNCT00362882 · 2006-07-01

Bortezomib in Treating Patients With Malignant Pleural MesotheliomaNCT00513877 · 2006-05-01

Bortezomib (Velcade) + Pemetrexed (Alimta) in Advanced NSCLCNCT00516100 · 2006-01-01

Bortezomib and Cetuximab in Treating Patients With Advanced Solid TumorsNCT00622674 · 2005-11-01

Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerNCT00118183 · 2005-07-01

Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung CancerNCT00118144 · 2005-06-01

Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid TumorsNCT00389805 · 2005-03-01

Bortezomib and Topotecan in Treating Patients With Advanced Solid TumorsNCT00388089 · 2004-12-01

Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung CancerNCT00093756 · 2004-09-01

Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung CancerNCT00075751 · 2004-01-01

Bortezomib in Treating Patients With Recurrent or Refractory Extensive-Stage Small Cell Lung Cancer Previously Treated With Platinum-Based ChemotherapyNCT00068289 · 2003-09-01

Bortezomib With or Without Docetaxel in Treating Patients With Relapsed or Refractory Advanced Non-Small Cell Lung CancerNCT00064012 · 2003-05-01

Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung CancerNCT00052338 · 2002-09-01

Bortezomib in Treating Patients With Advanced Non-small Cell Lung CancerNCT00040768 · 2002-04-01

PS-341 in Treating Women With Metastatic Breast CancerNCT00028639 · 2001-08-01

PS-341 in Treating Women With Metastatic Breast CancerNCT00025584 · 2001-08-01

Common conditions

Leading sponsors

National Cancer Institute (NCI) 8 Masonic Cancer Center, University of Minnesota 2 University of California, Davis 2 University of Wisconsin, Madison 2 Aptium Oncology Research Network 1 Cancer Trials Ireland 1 Chinese SLE Treatment And Research Group 1 European Organisation for Research and Treatment of Cancer - EORTC 1 Northwestern University 1 SWOG Cancer Research Network 1 University of Medicine and Dentistry of New Jersey 1

Trial status mix

COMPLETED18

UNKNOWN2

TERMINATED1

Phase mix

PHASE215

PHASE18

NA1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.